Teclistamab: Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

A retrospective study examined 39 adults with multiple myeloma who were treated with teclistamab between October 2022 and June 2023. Three patients developed cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) as a result of the treatment. The patients experienced varying grades of CRS and ICANS and were admitted to the hospital. However, all patients were able to complete the teclistamab treatment. [Extracted from the article]